Cell Genesys (CEGE) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Genesys (CEGE)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: sam who wrote (952)	6/12/2000 9:26:00 AM
From: david james	of 1298

Abgenix moving up before the open. Looks like 123. With 4.852 million shares, they have stock worth $600 million + over $250 million in cash. That gives $850 mill. Throw in a few million for their facilities and you have a book value over $25/share. They also have revenues of $40 mill + around $12 to $15 million interest on their cash. That should be enough to be profitable independent of the gain from the cash. They have a drug pipeline for the following Cancer vaccines GVAX© Prostate Cancer (should reach Phase III this year) GVAX© Pancreatic Cancer GVAX© Lung Cancer GVAX© Myeloma GVAX© Leukemia Gene therapy for Hemophilia A Hemophilia B Antiangiogenesis Restenosis Parkinson's Disease They also have the gene activation licensing program. The deal with Aventis and Transkaryotic is the most visible example of this and could generate significant revenues as early as next year. I notice that CNBC is doing interviews at the Goldman Sachs conference. So there is a chance the rumor is correct.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next